Apigenin and Placental β‐Endorphin Signaling: A Hypothesis‐Generating Mechanistic Review

The placenta functions as a dynamic endocrine hub that translates maternal exposures into offspring developmental programming, consistent with the Developmental Origins of Health and Disease (DOHaD) framework. Beta‐endorphin (β‐EP), a placental POMC‐derived opioid peptide, signals through MOR/DOR/KOR receptors to regulate angiogenesis, immune tolerance, oxidative stress, inflammation, and nutrient transport. Apigenin, a dietary flavone found in parsley, chamomile, and celery, modulates several pathways that overlap with this axis, including CREB/PKA signaling, DNA methyltransferase activity, Nrf2, NF‐κB/NLRP3, and Foxp3 + Treg differentiation, although most supporting evidence derives from non‐placental systems such as cancer lines, keratinocytes, and macrophages. This review proposes that apigenin may amplify placental β‐EP signaling across three conceptual tiers: a biosynthetic tier involving CREB/PKA‐mediated POMC activation and 11β‐HSD1 inhibition; a receptor‐level tier involving DNMT1/3a inhibition and OPRM1 demethylation; and an effector‐level tier involving Nrf2 activation, NF‐κB/NLRP3 suppression, and Treg expansion, the last representing the strongest trophoblast‐level evidence. Given reported β‐EP dysregulation in preeclampsia, gestational diabetes, preterm birth, and intrauterine growth restriction, apigenin's relevance to these disorders remains an untested hypothesis rather than a validated therapeutic strategy, informed by a structured, non‐systematic literature search (1986–2026).